论文部分内容阅读
目的探讨通心络联合纤溶酶治疗进展性脑梗塞的疗效和安全性。方法对126例确诊为进展性脑梗死的患者随机分为两组,治疗组(63例)用纤溶酶100U,1次/d静脉滴注,加用通心络胶囊3粒/次,3次/d,连用5～7d;对照组(63例)用低分子肝素钙4100U脐周皮下注射,1次/12h,连续5～7d。根据神经功能缺损程度评分标准和不良反应观察治疗效果。结果治疗组疗效明显优于对照组,差异有统计学意义(P<0.05)。结论通心络联合纤溶酶治疗作用显著,是治疗进展性脑梗死的有效措施。
Objective To investigate the efficacy and safety of Tongxinluo combined with plasmin in the treatment of advanced cerebral infarction. Methods One hundred and sixty-six patients diagnosed as progressive cerebral infarction were randomly divided into two groups. The treatment group (63 cases) received intravenous infusion of plasmin 100U once / d plus 3 capsules of Tongxinluo capsule, 3 Times a day for 5-7 days. The control group (63 cases) was subcutaneously injected with 4100U low molecular weight heparin calcium once a day for 5 to 7 days. According to the degree of neurological deficit score and adverse reactions to observe the therapeutic effect. Results The treatment group was significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion Tongxinluo combined with plasmin has a significant therapeutic effect, which is an effective measure for the treatment of progressive cerebral infarction.